ICHOM

Colorectal Cancer

Treatment approach covered

Surgery | Radiotherapy | Chemotherapy | Targeted therapy



Details

- 1 Complications will be recorded based on the type of therapy needed or action required to correct the complication as described in the Clavien-Dindo Classification and CTCAE v4.0.
- 3, 4 Recommeded to track via the EORTC Quality of Life Questionnaire -Core Questionnaire (EORTC QLQ-C30).
- 5 Includes bowel functioning, fecal leakage, stool frequency, diarrhea and dietary issues. Recommeded to track via the dietary subscale of the Memorial Sloan-Kettering Cancer Center (MSKCC) Bowel Function. Recommeded to track via the EORTC Quality of Life Questionnaire - Colorectal Cancer Module (EORTC QLQ-CR29).
- 6 Recommended to track via a single item from the EORTC Quality of Life Questionnaire Liver Metastases Colorectal Module (EORTC QLQ-LMC21).
- 7 Recommended to track via the EORTC Quality of Life Questionnaire Colorectal Cancer Module (EORTC QLQ-CR29).
- 8 Includes erectile dysfunction and vaginal symptoms. Recommended to track via the EORTC Quality of Life Questionnaire - Colorectal Cancer Module (EORTC QLQ-CR29).
- 9 Includes physical, emotional and social functioning and mobility and overall well-being. Recommended to track via the EORTC Quality of Life Questionnaire -Core Questionnaire (EORTC QLQ-C30).
- 10 Includes cause of death.
- 11 Includes pathologic complete response, margin status and recurrence and progression free survival.
- 12 includes place of death and preference for place of death according to the patient.

For a complete overview of this Set, including definitions for each measure, time points for collection, and associated risk factors, visit https://connect.ichom.org/patient-centered-outcome-measures/colorectal-cancer/



Contributors

For more information about the process of developing a Set of Patient-Centered Outcome Measures, visit ichom.org/how-we-work/

The Sponsors







The Working Group



Australia

Donna Bauer* | Bowel Cancer Australia Craig Lynch | Peter MacCallum Cancer Center

John ZalcBerg | Monash University

Belgium

Eric van Cutsem | Leuven Cancer Institute

Germany

Corinna Langelotz | Universitätsmedizin Berlin-Charité

Malaysia

Muhammad Radzi Abu Hassan | Hospital Sultanah Bahiyah

Netherlands

Rob Tollenaar | Leiden University Medical Center

Cornelis van de Velde | Leiden University Medical Center

Eino van Duyn | Medisch Spectrum Twente

Singapore

Joanne Ngeow | National Cancer Centre Singapore

Spair

Josep Borras | University of Barcelona

Taiwar

Skye Hung-Chung Chen | Koo Foundation Sun Yat-Sen Cancer Center

United Kingdom

Michael Fenn* | AOL community

United States

Ann Berger | University of Nebraska Medical Center

Giles Boland | Harvard Medical School

Robert Cima | Robert Cima Sam Finlayson | University of Utah John Lloyd* | Colon Cancer Alliance Harvey Mamon | Dana Farber Cancer

Institute
Pamela McAllister* | Fight Colorectal
Cancer

Bruce Minsky | MD Anderson Cancer Center Kim Ryan* | Cancer Support Community

Veena Shankaran | University of Washington Medical Center

Melissa Upton | University of Washington Medical Center

Jessica Zerillo | Beth Israel Deaconess Medical Center

*Patient representative